DK2196545T3 - Fremgangsmåder til forudsigelse af reaktionen hos patienter med dissemineret sclerose på interferonbehandling samt diagnosticering af dissemineret sclerose - Google Patents
Fremgangsmåder til forudsigelse af reaktionen hos patienter med dissemineret sclerose på interferonbehandling samt diagnosticering af dissemineret scleroseInfo
- Publication number
- DK2196545T3 DK2196545T3 DK10003542.7T DK10003542T DK2196545T3 DK 2196545 T3 DK2196545 T3 DK 2196545T3 DK 10003542 T DK10003542 T DK 10003542T DK 2196545 T3 DK2196545 T3 DK 2196545T3
- Authority
- DK
- Denmark
- Prior art keywords
- disseminated sclerosis
- predicting
- diagnosis
- patients
- procedures
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06003978A EP1826277A1 (en) | 2006-02-27 | 2006-02-27 | Methods for predicting the response of multiple sclerosis patients to interferon therapy and diagnosing multiple sclerosis |
| EP07711702A EP1991696B1 (en) | 2006-02-27 | 2007-02-27 | Methods for predicting the response of multiple sclerosis patients to interferon therapy and diagnosing multiple sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2196545T3 true DK2196545T3 (da) | 2012-07-16 |
Family
ID=36658688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10003542.7T DK2196545T3 (da) | 2006-02-27 | 2007-02-27 | Fremgangsmåder til forudsigelse af reaktionen hos patienter med dissemineret sclerose på interferonbehandling samt diagnosticering af dissemineret sclerose |
| DK07711702.6T DK1991696T3 (da) | 2006-02-27 | 2007-02-27 | Fremgangsmåde til diagnosticering af et anlæg hos patienter med dissemineret sclerose for modtagelighed for interferonterapi samt til diagnosticering af dissemineret sclerose |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07711702.6T DK1991696T3 (da) | 2006-02-27 | 2007-02-27 | Fremgangsmåde til diagnosticering af et anlæg hos patienter med dissemineret sclerose for modtagelighed for interferonterapi samt til diagnosticering af dissemineret sclerose |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8071299B2 (da) |
| EP (4) | EP1826277A1 (da) |
| AT (2) | ATE466959T1 (da) |
| DE (1) | DE602007006284D1 (da) |
| DK (2) | DK2196545T3 (da) |
| SI (1) | SI2196545T1 (da) |
| WO (1) | WO2007096197A2 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2207902A1 (en) * | 2007-11-09 | 2010-07-21 | INSERM (Institut National de la Santé et de la Recherche Medicale) | A method for predicting the therapeutic responsiveness of patients to a medical treatment with an interferon |
| US20110091422A1 (en) * | 2008-07-24 | 2011-04-21 | Merck Serono Sa | Use of Genetic Markers for Identifying the Response to Interferon Treatment in Multiple Sclerosis Patients |
| WO2011117267A1 (en) * | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
| EP2380992A1 (en) * | 2010-04-21 | 2011-10-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Methods for predicting an antibody response to interfer on therapy in multiple sclerosis patients |
| JP2020506477A (ja) * | 2017-01-27 | 2020-02-27 | オリジェン， インコーポレイテッド | 個人遺伝子のプロフィールに基づいて購入勧告を決定して、提示するためのシステム及び方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1114998A3 (en) | 1999-10-28 | 2001-08-22 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Method for determining the success rate of treatment of multiple sclerosis |
| WO2003014319A2 (en) | 2001-08-07 | 2003-02-20 | Genaissance Pharmaceuticals, Inc. | Polymorphisms associated with multiple sclerosis |
| SE0103423D0 (sv) | 2001-10-12 | 2001-10-12 | Astrazeneca Ab | Polymorphism |
| GB0307914D0 (en) | 2003-04-07 | 2003-05-14 | Univ Dundee | Cytochrome p450 |
| US20090011407A1 (en) * | 2003-11-26 | 2009-01-08 | The Ohio State University Research Foundation | Polymorphic Cd24 Genotypes that are Predictive of Multiple Sclerosis Risk and Progression |
-
2006
- 2006-02-27 EP EP06003978A patent/EP1826277A1/en not_active Withdrawn
-
2007
- 2007-02-27 AT AT07711702T patent/ATE466959T1/de not_active IP Right Cessation
- 2007-02-27 EP EP10003542A patent/EP2196545B1/en not_active Not-in-force
- 2007-02-27 DE DE602007006284T patent/DE602007006284D1/de active Active
- 2007-02-27 AT AT10003542T patent/ATE557102T1/de active
- 2007-02-27 SI SI200730969T patent/SI2196545T1/sl unknown
- 2007-02-27 DK DK10003542.7T patent/DK2196545T3/da active
- 2007-02-27 WO PCT/EP2007/001689 patent/WO2007096197A2/en active Application Filing
- 2007-02-27 US US12/280,665 patent/US8071299B2/en not_active Expired - Fee Related
- 2007-02-27 EP EP07711702A patent/EP1991696B1/en not_active Not-in-force
- 2007-02-27 DK DK07711702.6T patent/DK1991696T3/da active
- 2007-02-27 EP EP10003543A patent/EP2196546B1/en not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| DK1991696T3 (da) | 2010-08-30 |
| EP1991696B1 (en) | 2010-05-05 |
| EP2196545A1 (en) | 2010-06-16 |
| US8071299B2 (en) | 2011-12-06 |
| ATE466959T1 (de) | 2010-05-15 |
| EP2196545B1 (en) | 2012-05-09 |
| EP1991696A2 (en) | 2008-11-19 |
| EP1826277A1 (en) | 2007-08-29 |
| ATE557102T1 (de) | 2012-05-15 |
| WO2007096197A2 (en) | 2007-08-30 |
| EP2196546A1 (en) | 2010-06-16 |
| US20090186773A1 (en) | 2009-07-23 |
| WO2007096197A3 (en) | 2007-10-18 |
| EP2196546B1 (en) | 2013-02-27 |
| SI2196545T1 (sl) | 2012-09-28 |
| DE602007006284D1 (de) | 2010-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2126828A4 (en) | SYSTEMS AND METHODS FOR UNDERSTANDING AND APPLYING THE PHYSIOLOGICAL AND CONTEXTUAL LIFE PATTERNS OF ONE OR MORE INDIVIDUALS | |
| WO2007005623A3 (en) | System and method for providing individually tailored health-promoting information | |
| EP2083897A4 (en) | PATIENT INTERFACE SYSTEMS | |
| DK2046819T3 (da) | Fremgangsmåder til forøgelse af secernering af polypeptider med biologisk aktivitet | |
| DK3056568T3 (da) | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik | |
| WO2010101641A3 (en) | Galvanic vestibular stimulation system and method of use for simulation, directional cueing, and alleviating motion-related sickness | |
| FR2908628B1 (fr) | Procede et systeme de pilotage d'un instrument medical | |
| DE602005001521D1 (de) | Spritzenset für Ballonkatheter | |
| EP2273918A4 (en) | METHODS, SYSTEMS AND DEVICES FOR DETECTING AND DIAGNOSIS OF HEART DISEASES AND DRESSES | |
| ATE375518T1 (de) | Diagnoseverfahren für erkrankungen unter verwendung von copeptin | |
| DK2196545T3 (da) | Fremgangsmåder til forudsigelse af reaktionen hos patienter med dissemineret sclerose på interferonbehandling samt diagnosticering af dissemineret sclerose | |
| DE602005015418D1 (de) | Überwachungssystem für den menschlichen körper | |
| DE602006015256D1 (de) | Verfahren und System zur Ortsbestimmung für einen Termin mittels Navigationssystem | |
| DK1817282T3 (da) | Til behandling af respiratoriske sygdomme egnede phenoxy derivater | |
| ITPI20060094A1 (it) | Apparecchiatura per la valutazione dell'acuita' visiva di un individuo. | |
| ITPS20060008A1 (it) | Metodo per la valutazione della protezione da agenti biologici di dispositivi di protyezione individuale per le vie respiratorie | |
| LTPA2018503I1 (lt) | Kladribino režimas, skirtas išsėtinei sklerozei gydyti | |
| ITMO20050159A1 (it) | Sistema per il controllo dell'umidita'. | |
| DE602006015265D1 (de) | System und Verfahren zur Aufzugsgruppensteuerung | |
| FI20050263A0 (fi) | Hissiryhmä ja menetelmä hissiryhmän ohjaamiseksi | |
| WO2007100980A3 (en) | Electronic contracting | |
| FR2909180B1 (fr) | Methode de mesure fonctionnelle de l'activite de la thrombomoduline plasmatique. | |
| EP2134863A4 (en) | GENETIC MODIFICATIONS ON CHROMOSOME 16 AND METHODS OF USING THE SAME FOR THE DIAGNOSIS AND TREATMENT OF TYPE I DIABETES | |
| DK1856070T3 (da) | Nye lægemidler til behandling af luftvejssygdomme | |
| WO2005079284A3 (en) | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |